{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:41:52Z","timestamp":1786372912019,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.2215\/cjn.13411119","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T15:55:16Z","timestamp":1590594916000},"page":"1041-1043","source":"Crossref","is-referenced-by-count":17,"title":["Secondary Hyperparathyroidism in a Patient with CKD"],"prefix":"10.2215","volume":"15","author":[{"given":"Ryyan","family":"Hyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-0179","authenticated-orcid":false,"given":"Stuart M.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol Rev"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat Commun"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE trial","volume":"30","author":"Ix","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease","volume":"27","author":"Zisman","year":"2007","journal-title":"Am J Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfx059","article-title":"High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD stages 3-4: Results of a 12-week double-blind, randomized, controlled study","volume":"33","author":"Westerberg","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40620-015-0186-0","article-title":"Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low","volume":"29","author":"Ennis","year":"2016","journal-title":"J Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2215\/CJN.03850609","article-title":"Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease","volume":"5","author":"Sprague","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2215\/CJN.10390917","article-title":"Parathyroidectomy in the management of secondary hyperparathyroidism","volume":"13","author":"Lau","year":"2018","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13411119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:51Z","timestamp":1786369191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13411119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13411119","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]}}}